MX2021011677A - Uso del gen kdm5a y del gen atrx. - Google Patents
Uso del gen kdm5a y del gen atrx.Info
- Publication number
- MX2021011677A MX2021011677A MX2021011677A MX2021011677A MX2021011677A MX 2021011677 A MX2021011677 A MX 2021011677A MX 2021011677 A MX2021011677 A MX 2021011677A MX 2021011677 A MX2021011677 A MX 2021011677A MX 2021011677 A MX2021011677 A MX 2021011677A
- Authority
- MX
- Mexico
- Prior art keywords
- gene
- kdm5a
- atrx
- application
- chiauranib
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57423—Specifically defined cancers of lung
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente invención proporciona el uso del gen KDM5A y/o del gen ATRX como biomarcadores para evaluar la eficacia de Chiauranib o guiar la administración de Chiauranib, así como el uso de Chiauranib para la producción de un fármaco para el tratamiento de pacientes con cáncer de pulmón de células pequeñas con mutaciones genéticas en el gen KDM5A o en el gen ATRX.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910228411 | 2019-03-25 | ||
PCT/CN2020/080579 WO2020192606A1 (zh) | 2019-03-25 | 2020-03-23 | Kdm5a基因和atrx基因的应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2021011677A true MX2021011677A (es) | 2021-10-22 |
Family
ID=72610972
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2021011677A MX2021011677A (es) | 2019-03-25 | 2020-03-23 | Uso del gen kdm5a y del gen atrx. |
Country Status (12)
Country | Link |
---|---|
US (1) | US20220184056A1 (es) |
EP (1) | EP3950961A4 (es) |
JP (1) | JP2022527895A (es) |
KR (1) | KR20210143866A (es) |
CN (1) | CN111733235A (es) |
AU (1) | AU2020246335A1 (es) |
BR (1) | BR112021019155A2 (es) |
CA (1) | CA3134620A1 (es) |
MX (1) | MX2021011677A (es) |
TW (1) | TWI798532B (es) |
WO (1) | WO2020192606A1 (es) |
ZA (1) | ZA202108165B (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI797426B (zh) * | 2019-03-25 | 2023-04-01 | 大陸商深圳微芯生物科技股份有限公司 | 西奧羅尼用於小細胞肺癌的治療 |
CN112111577B (zh) * | 2020-10-23 | 2022-09-06 | 北京诺禾致源科技股份有限公司 | 基于数字pcr技术的atrx和kdm5a突变检测的试剂盒、装置及应用 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HUE046790T2 (hu) * | 2012-10-15 | 2020-03-30 | Epizyme Inc | A rák kezelésének módszerei |
EP2929350A4 (en) * | 2012-12-04 | 2016-11-16 | Caris Mpi Inc | MOLECULAR PROFILING FOR CANCER |
CN105339001A (zh) * | 2013-03-15 | 2016-02-17 | 基因泰克公司 | 治疗癌症和预防癌症耐药性的方法 |
CN105512142A (zh) * | 2014-09-26 | 2016-04-20 | 深圳华大基因股份有限公司 | 基因变异与药物关系数据库和数据库系统 |
US20180045727A1 (en) * | 2015-03-03 | 2018-02-15 | Caris Mpi, Inc. | Molecular profiling for cancer |
EP3265562A4 (en) * | 2015-03-05 | 2018-12-19 | TrovaGene, Inc. | Early assessment of mechanism of action and efficacy of anti-cancer therapies using molecular markers in bodily fluids |
CN105512412A (zh) * | 2015-12-11 | 2016-04-20 | 中国北方发动机研究所(天津) | 一种增压发动机排气系统匹配优劣的评价方法 |
-
2020
- 2020-02-26 TW TW109106184A patent/TWI798532B/zh active
- 2020-03-23 CN CN202010211409.3A patent/CN111733235A/zh active Pending
- 2020-03-23 JP JP2021557124A patent/JP2022527895A/ja not_active Withdrawn
- 2020-03-23 US US17/442,886 patent/US20220184056A1/en active Pending
- 2020-03-23 KR KR1020217034496A patent/KR20210143866A/ko not_active Application Discontinuation
- 2020-03-23 CA CA3134620A patent/CA3134620A1/en active Pending
- 2020-03-23 EP EP20777844.0A patent/EP3950961A4/en not_active Withdrawn
- 2020-03-23 BR BR112021019155A patent/BR112021019155A2/pt unknown
- 2020-03-23 WO PCT/CN2020/080579 patent/WO2020192606A1/zh unknown
- 2020-03-23 MX MX2021011677A patent/MX2021011677A/es unknown
- 2020-03-23 AU AU2020246335A patent/AU2020246335A1/en not_active Abandoned
-
2021
- 2021-10-22 ZA ZA2021/08165A patent/ZA202108165B/en unknown
Also Published As
Publication number | Publication date |
---|---|
KR20210143866A (ko) | 2021-11-29 |
TWI798532B (zh) | 2023-04-11 |
EP3950961A4 (en) | 2023-01-25 |
AU2020246335A1 (en) | 2021-11-18 |
JP2022527895A (ja) | 2022-06-07 |
BR112021019155A2 (pt) | 2022-02-15 |
TW202035700A (zh) | 2020-10-01 |
CN111733235A (zh) | 2020-10-02 |
EP3950961A1 (en) | 2022-02-09 |
CA3134620A1 (en) | 2020-10-01 |
ZA202108165B (en) | 2023-06-28 |
US20220184056A1 (en) | 2022-06-16 |
WO2020192606A1 (zh) | 2020-10-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2020008882A (es) | Dosificación para tratamiento con anticuerpos antagonistas anti-tigit y anti-pd-l1. | |
SA521422304B1 (ar) | مركبات تشارك في الارتباط التعاوني واستخداماتها | |
MX2019001920A (es) | Arn la terapia contra el cancer. | |
MX2018002723A (es) | Macrociclicos peptidomimeticos y usos de los mismos. | |
MX2017014338A (es) | Seleccion dirigida de pacientes para el tratamiento con derivados de cortistatina. | |
PH12016500575A1 (en) | Inhibitors of bruton`s tyrosine kinase | |
PH12015502362A1 (en) | Certain chemical entities, compositions and methods | |
MX2020010412A (es) | Inhibidores de tirosina quinasa de bruton. | |
WO2016196776A3 (en) | Inhibitors of bruton's tyrosine kinase | |
TN2015000174A1 (en) | Pyrrolopyrimidine compounds as kinase inhibitors | |
PH12019500892A1 (en) | Treating gastric cancer using combination therapies comprising liposomal irinotecan, oxaliplatin, 5-fluoruracil (and leucovorin) | |
MX2017004128A (es) | Derivados de diarilurea como inhibidores de quinasa p38. | |
PH12020551043A1 (en) | Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues | |
MX2017016134A (es) | Aril dihidro-2h-benzo[b][1,4]oxazina sulfonamida y compuestos relacionados para uso como agonistas de rory y el tratamiento de enfermedad. | |
EA201890957A1 (ru) | Комбинированная терапия для лечения злокачественных опухолей | |
MX2019012464A (es) | Terapia combinada con un conjugado de anticuerpo y farmaco anti-axl. | |
MX2024000253A (es) | Inhibicion del smarca2 para el tratamiento del cancer. | |
MX2019005435A (es) | Composicion farmaceutica, metodos para tratamiento y sus usos. | |
BR112014029954A2 (pt) | tratamento de tumores sólidos usando coenzima q10 | |
PH12018502422A1 (en) | Nanoliposomal irinotecan for use in treating small cell lung cancer | |
MX2019015676A (es) | Uso de isovaleril espiramicina i, ii y/o iii en la fabricación de medicamentos para el tratamiento y/o la prevención de tumores, y el medicamento. | |
MX2021011677A (es) | Uso del gen kdm5a y del gen atrx. | |
MX2022006853A (es) | Macrociclos para uso en el tratamiento de enfermedades. | |
MX2020000118A (es) | Composiciones y metodos para mejorar la funcion cardiaca. | |
CL2015001574A1 (es) | Terapia combinada para el cancer |